| | & The Daily Upside | Good day, 360! | Here are some of our top movers today. And don’t forget to join us in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | VRPX- Up over 70% in the pre-market after announcing agreement with the U.S. Department of Health and Human Services for the developmental extension for NES100 towards IND for Acute and Chronic Non-Cancer Pain Alternative | BENF - Up over 25% in the pre-market after announcing it had reported to the Kansas Legislative Committee on Its positive developments and the digital transformation of the alternative asset industry | GAP - Up over 15% in pre after reporting better than expected earnings, raising full year outlook | | *sponsored by Upmarket | 5 Ways UpMarket Transforms Your Investment Strategy | | Are you looking to build a more diversified portfolio or access new investments? | UpMarket offers hedge funds, pre-IPO investments, and more. | With UpMarket, you can: | Access top-tier hedge funds with lower minimums Diversify with pre-IPO companies, private equity, and more Enjoy a modern, all-online investment experience Benefit from a curated selection of hedge funds and other alternatives Join a platform that's deployed $150M+ for investors just like you | Ready to take your portfolio UpMarket? | Start Investing Today |
|
| | HOTLIST🔥 | VRPX- Up over 70% in the pre-market after announcing agreement with the U.S. Department of Health and Human Services for the developmental extension for NES100 towards IND for Acute and Chronic Non-Cancer Pain Alternative | Virpax Pharmaceuticals Inc. (VRPX) is a preclinical-stage pharmaceutical company that develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. | In the after-hours yesterday, the company announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. | This collaboration is for the continued development of Virpax’s product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. | NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. | Shares of VRPX traded up over 70% in the pre-market in reaction to the news. | | The $1 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.10, $1.20 and then the pre-market high at $1.29. Beyond that, $1.50, $1.70 and $1.90 come into play. | Below $1, targets to the downside are $0.90, $0.80, $0.70 and then a gap fill at $0.5897. | | BENF - Up over 25% in the pre-market after announcing it had reported to the Kansas Legislative Committee on Its positive developments and the digital transformation of the alternative asset industry | Beneficient (BENF) is a technology-enabled financial services company that provides liquidity solutions and related trustee, custody and trust administrative services to participants in the alternative asset industry in the United States. It operates through Ben Liquidity, Ben Custody, and Customer ExAlt Trusts segments. | In the after hours yesterday, the company announced that it had provided an update to the State of Kansas Joint Committee on Fiduciary Financial Institutions Oversight about its business operations, the digital innovation occurring in the alternative asset industry and related economic development activity for the benefit of Kansas communities under the Kansas Technology-Enabled Fiduciary Financial Institutions (TEFFI) Act (“Act”). | As part of its update, the company emphasized BENF’s continued advancement of its financial industry focused business through new technology innovation, an authorization by BENF’s board of directors to complete up to $5 billion in fiduciary financings and a transaction involving the reclassification of certain preferred equity that increased Beneficient’s permanent equity by $126 million. | Shares of BENF traded up over 25% in the pre-market in reaction to the news. | | The $1 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1.10, $1.15, $1.20 and then the pre-market high at $1.25 and then the pre-market high at $1.28. Beyond that, $1.40, $1.75 and $2.10 come into play. | Below $1, there is a gap fill at $0.88 and then $0.80 after that. | | *sponsored by The Daily Upside | Savvy Investors Know Where to Get Their News—Do You? | Here’s the truth: there is no magic formula when it comes to building wealth. | Much of the mainstream financial media is designed to drive traffic, not good decision-making. Whether it’s disingenuous headlines or relentless scare tactics used to generate clicks, modern business news was not built to serve individual investors. | Luckily, we have The Daily Upside. Created by Wall Street insiders and bankers, this fresh, insightful newsletter delivers valuable insights that go beyond the headlines. | And the best part? It’s completely free. Join 1M+ readers and subscribe today. |
|
| | GAP - Up over 15% in pre after reporting better than expected earnings, raising full year outlook | The Gap, Inc. operates as an apparel retail company. The company offers apparel, accessories, and personal care products for men, women, and children under the Old Navy, Gap, Banana Republic, and Athleta brands. | In the after-hours yesterday, the company reported financial results for its third quarter ended November 2, 2024. | Highlights Include: | -Net sales increased 2% versus last year with comparable sales up 1% | -Operating margin of 9.3% improved 270 basis points versus last year | -Market share gains across all brands in the quarter | -Raises outlook for fiscal 2024 net sales, gross margin and operating income growth | | Shares of GAP traded up over 15% in the pre-market in reaction to the earnings results. | | | | The first target for bulls is the pre-market high at $25.60. Beyond that, $26, $27, $29 and $30.75 come into play. | Below $25.60, targets to the downside are $25, $24.50, $23 and then a gap fill at $22.04. | | MARKET NEWS 📰 | | P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
